普沐

Pumu Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of innovative antibody-based therapeutics. The company leverages its proprietary antibody engineering platforms to target high-value pathways in immunology, inflammation, and oncology. Its lead programs include PM-1001, an anti-IL-17A antibody for psoriasis, and PM-1002, an anti-IL-4Rα antibody for atopic dermatitis and asthma. Pumu Bio focuses on creating differentiated biologics that offer improved efficacy and safety profiles compared to existing treatments. By integrating deep biological insights with advanced protein engineering, the company aims to address significant unmet medical needs globally. The firm is backed by prominent venture capital firms and maintains a robust R&D facility in Shanghai.